New OHE insight on immunisation: despite high returns on investment, global spending lags. We outline why and how countries ...

Analysis of Trump’s ‘Most Favoured Nation’ Executive Order on drug pricing, its global impact, price convergence aims, and ...

Neil McAuslane PhD, MSc, BSc. Scientific Director of the Centre for Innovation in Regulatory Science (CIRS) overseeing the scientific content of both CIRS regulatory and HTA programmes. Key research ...

Kiran Bhatti joined OHE in March 2025 as a Business Executive. She holds an MBA Master of Business Administration degree. She is a finance professional with over 18 years’ experience in business ...

Despite substantial medical advancements that have transformed HIV into a manageable chronic condition for individuals, the ...

To help inform the current debate on assisted dying, we have updated the findings of our 2019 palliative report with the latest data. A previous OHE report in 2019 estimated that 378, 427 people in ...

In this fourth and final blog in our AMR series, we set out a positive scenario for tackling antibiotic resistance, and contemplate other possibilities. This article was commissioned by Pfizer Inc.

Andrew is a leading expert in health economic evaluation, with a particular focus on statistical methods for cost-effectiveness analysis. His work encompasses parameter estimation for economic models, ...

In England, an estimated 378,427 people receive palliative care each year in a range of specialised and generalised services. Overall, the quality of palliative care in England and the wider UK is ...

In this report, we highlight the significance of prevention as a cost-effective and often cost-saving investment for public sector resources. Prevention, covering primary, secondary, and tertiary ...

Within this report, we summarise the Digital Health Landscape in the UK. We include areas of regulation, value assessment and reimbursement, and efforts to increase the digital literacy of the general ...